American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Enzyme Inhibitors
  • Estrogen Antagonists
  • Raloxifene Hydrochloride
  • Tamoxifen

abstract

  • The conclusions were endorsed by the ASCO Health Services Research Committee and the ASCO Board of Directors.

publication date

  • August 2002

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2002.06.029

PubMed ID

  • 12149307

Additional Document Info

start page

  • 3328

end page

  • 43

volume

  • 20

number

  • 15